| Literature DB >> 26609939 |
Erik S Van Dis1, Tyler C Moore1, Kerry J Lavender1, Ronald J Messer1, Oliver T Keppler2, Jens Verheyen3, Ulf Dittmer3, Kim J Hasenkrug4.
Abstract
Amyloid fibrils from semen-derived peptide (SEVI) enhance HIV-1 infectivity in vitro but the ability of SEVI to mediate enhancement of HIV infection in vivo has not been tested. In this study we used immunodeficient mice reconstituted with human immune systems to test for in vivo enhancement of HIV-1 transmission. This mouse model supports mucosal transmission of HIV-1 via the intrarectal route leading to productive infection. In separate experiments with humanized mouse cohorts reconstituted with two different donor immune systems, high dose HIV-1JR-CSF that had been incubated with SEVI amyloid fibrils at physiologically relevant concentrations did not show an increased incidence of infection compared to controls. In addition, SEVI failed to enhance rectal transmission with a reduced concentration of HIV-1. Although we confirmed potent SEVI-mediated enhancement of HIV infectivity in vitro, this model showed no evidence that it plays a role in the much more complex situation of in vivo transmission. Published by Elsevier Inc.Entities:
Keywords: Amyloid; HIV; Humanized mice; SEVI; Semen-derived enhancer of viral infection; Transmission
Mesh：
Substances：
Year: 2015 PMID： 26609939 PMCID： PMC4744509 DOI： 10.1016/j.virol.2015.11.005
Source DB: PubMed Journal: Virology ISSN： 0042-6822 Impact factor: 3.616